HOUSTON, TX--(Marketwire - May 6, 2008) - Symmetry Technologies, Inc. (PINKSHEETS: SMMR) - In addition to a full line of pharmaceutical and nutriceutical products, the company has licensed and has begun developing a rejuvenation program therapy that features a medley of FDA approved prescription and non prescription drugs that offers an intracellular approach to slowing and possibly reversing the aging process in humans.

"It is well established that the primary biological cause of aging is the increasing proportion of senescent cells in the body. Cell senescence is the result of reduction in the telomere length of the individual cells as they repeatedly divide to replace dead cells," explains Symmetry President Chad Reed. "Our rejuvenation therapy process employs a process of selective chemical pruning of senescence cells and replenishment by stimulating the production and conversion of adult stem cells to cells with full (youthful) telomere length." Telomere length is the most reliable biological age marker, length inversely proportional to age. The Company's research in this area is being pursued in cooperation with Quantum Bit Induction Technology, Inc. www.quantumbit.com and a small group of Ph.D. biologists.

"Another overlooked aging problem," continues Mr. Reed, "is that virtually every human has contracted some strain of the herpes virus, although in most people it is asymptomatic. There are many forms of herpes from simplex to chickenpox and multitudes of others. The herpes virus is introduced, to the general population, almost daily and accelerates cell senescence. We believe that the many forms of the, highly communicable, herpes virus slowly, almost imperceptibly, wreak havoc with the body's immune system and ultimately contribute substantially to the aging process."

Symmetry operates www.RapidScripts.net, which is a US online pharmacy. The Company carries a variety of products and is planning to add this proprietary combinatorial rejuvenation therapy to the product library. RapidScripts is an easy access Pharmacy with quality products priced very competitively.

This release contains statements that are based on the best judgment of the Company. The Company cautions all interested investors that many uncertainties exist and thorough due diligence should be undertaken by any person prior to making an investment decision. Anyone interested in the Company is invited to communicate with management through email, the address for which can be found on our corporate website www.symmetrytech.net.

HOUSTON, TX--(Marketwire - October 10, 2007) - Symmetry Technologies, Inc. (PINKSHEETS: SMMR) is isolating compounds that, it believes, will induce apoptosis in senescent cells, stimulate stem cell growth, and suppress herpes activity. The Company believes that by clearing tissues with short average telomere length and stimulating longer telomere cell growth, including differentiation from stem cell populations, while ameliorating the effects of HSV activity, they will produce an effect that is tantamount to cell rejuvenation. Symmetry is accomplishing these biological tasks using compounds that have been accepted as safe for human consumption and already approved for human use, believing that the "art" will be in producing the desired effect using combinations of such compounds. "The process of creating this product has been very interesting," said President Chad Reed. "This is the first of many products we hope to bring to the marketplace." The Company's research in this area is being pursued in cooperation with Quantum Bit Induction Technology, Inc. (www.quantumbit.com) and a small group of Ph.D. biologists.

Symmetry operates www.RapidScripts.net, which is a US online pharmacy. The Company carries a variety of products and is planning to add this proprietary combinatorial rejuvenation therapy to the product library in the future. RapidScripts is an easy-access pharmacy with quality products priced very competitively.

This release contains statements that are based on the best judgment of the Company. The Company cautions all interested investors that many uncertainties exist and thorough due diligence should be undertaken by any person prior to making an investment decision. Anyone interested in the Company is invited to communicate with management through email which can be found on our corporate website www.symmetrytech.net.

http://www.marketwire.com/press-release/Symmetry-Technologies-Inc-852956.html

http://www.marketwire.com/press-release/Symmetry-Technologies-Inc-779336.html